Pain and Bleeding in Early Pregnancy

Learning objectives#

• Stabilize and triage early-pregnancy pain and bleeding before relying on a hormone trend or ultrasound label.
• Use pregnancy of unknown location as a temporary classification with three major outcomes: early intrauterine pregnancy, ectopic pregnancy, or completed early pregnancy loss.
• Explain why one hCG value, a presumed discriminatory boundary, or one nondiagnostic scan cannot determine location.
• Design serial testing and repeat imaging with explicit emergency thresholds and closed-loop result ownership.
• Compare expectant, medical, and surgical branches for ectopic pregnancy while preserving contraindications, patient goals, and uncertainty.

Initial presentation#

A 31-year-old patient comes to an emergency department for six hours of intermittent left lower abdominal pain and light vaginal spotting. A home pregnancy test became positive four days ago. The pregnancy is desired. Based on the first day of her last menstrual period, she estimates that she may be five to six weeks pregnant, but her cycles range from 30 to 42 days and she does not know when ovulation occurred.

The pain is currently mild and has not become sudden or severe. She has used one pad in six hours without soaking it. There is no shoulder-tip pain, fainting, weakness, shortness of breath, fever, vomiting, or passage of tissue, and she has had no prior ectopic pregnancy, pelvic surgery, assisted reproduction, or known tubal disease. A remote treated sexually transmitted infection is possible but she is unsure which test was positive. The absence of a clear risk factor is not treated as clearance.

She has one prior early pregnancy loss managed without surgery. She takes a prenatal vitamin and no prescription medicine. There is no known bleeding disorder. She feels safe at home and asks that her partner join only after the initial discussion.

Blood pressure is 118/72 mm Hg, pulse 82 per minute, and temperature is normal. She is alert, well perfused, and not distressed. The abdomen is soft with mild left lower tenderness but no guarding or rebound. With consent and a chaperone, pelvic examination shows a small amount of blood, a closed-appearing cervix, and no marked cervical-motion or adnexal tenderness; the examination reduces concern for current rupture but cannot locate the pregnancy.

Problem representation#

This is a hemodynamically stable patient with a desired early pregnancy of uncertain gestational age, a positive pregnancy test, light bleeding, and mild unilateral pelvic pain. No prior imaging has confirmed an intrauterine pregnancy. Ectopic pregnancy remains the cannot-miss diagnosis even without classic risk factors or severe pain. The immediate questions are therefore whether there is bleeding or rupture requiring emergency intervention, whether transvaginal ultrasound shows a definite or probable pregnancy location, and whether she can safely complete serial follow-up if the first evaluation is nondiagnostic.

Prioritized differential#

1. Early intrauterine pregnancy not yet visible#

Reasoning for: Irregular cycles make calendar dating imprecise. A pregnancy can be earlier than the last menstrual period suggests, and an initial scan may precede visible structures. Light bleeding can occur in a pregnancy that continues.

Reasoning against or still uncertain: Pain and bleeding require evaluation, and nonvisualization does not establish a normal location. Only a later ultrasound showing accepted intrauterine structures can resolve this branch.

2. Tubal or other ectopic pregnancy#

Why it cannot be missed: Rupture can cause life-threatening internal bleeding. Ectopic pregnancy can present with mild or atypical symptoms, and many affected patients have no recognized risk factor.

Case evidence: Unilateral pain and spotting support consideration. Normal vital signs, mild tenderness, and no free-fluid result yet available lower concern for active rupture but do not exclude an unruptured ectopic pregnancy. Location must remain unresolved until evidence says otherwise.

3. Early pregnancy loss, resolving pregnancy of unknown location, or completed loss#

Bleeding may represent an early loss. However, passage of blood or tissue and a later empty uterus cannot establish a completed intrauterine loss unless an intrauterine pregnancy had previously been confirmed or follow-up resolves location. A falling hCG value can occur with a resolving ectopic pregnancy as well as an intrauterine loss.

4. Corpus luteum pain, hemorrhagic ovarian cyst, or adnexal torsion#

A corpus luteum is expected in early pregnancy and can cause unilateral discomfort. Cyst bleeding can mimic ectopic symptoms. Sudden severe pain, nausea, or an enlarged ovary might raise torsion concern. So might reduced blood flow. But Doppler flow alone cannot fully exclude torsion. Gynecologic consultation follows the whole picture.

5. Cervical, vaginal, or infectious bleeding#

Cervical ectropion, polyp, trauma, and cervicitis can cause spotting. Pelvic inflammatory disease is less common during established pregnancy but infection and sexually transmitted infections remain possible. Finding a cervical source would not by itself locate the pregnancy.

6. Urinary, gastrointestinal, or surgical disease#

Urinary infection, ureteral stone, and appendicitis can coexist with pregnancy. So can diverticular disease, gastroenteritis, and other abdominal conditions. Hematuria, urinary symptoms, or fever would redirect testing. So would migration of pain, peritoneal findings, or a changing laboratory pattern. A positive pregnancy test must not become a reason to ignore nonobstetric emergencies.

7. Heterotopic pregnancy#

Concurrent intrauterine and ectopic pregnancies are rare without assisted reproduction but more relevant after fertility treatment. Later confirmation of an intrauterine pregnancy would make ectopic pregnancy much less likely in this case, not impossible if severe or persistent adnexal symptoms emerge.

Focused history and examination#

Identify immediate danger#

• Ask about sudden or escalating pain, shoulder-tip pain, fainting, dizziness, weakness, shortness of breath, heavy bleeding, and reduced responsiveness.
• Quantify bleeding by change over time, product use, clots, and symptoms of blood loss rather than relying on the word spotting.
• Review prior hemoglobin, anemia, anticoagulant use, bleeding disorder, and transfusion history.

Establish pregnancy context and preferences#

• Record last menstrual period without assuming it gives exact gestational age. Ask about cycle length, contraception, fertility treatment, date of first positive test, prior ultrasound, and prior hCG results.
• Ask about previous ectopic pregnancy, pelvic or tubal surgery, pelvic infection, infertility, intrauterine device, smoking, and prior losses. Lack of these factors does not rule out ectopic pregnancy.
• Clarify whether the pregnancy is desired and how much diagnostic uncertainty the patient is prepared to tolerate. Do not infer preference from relationship, age, disability, or social situation.

Look for competing diagnoses and treatment constraints#

Review fever, gastrointestinal and urinary symptoms, sexual health, medications, allergies, kidney and liver disease, blood disorder, immune disorder, lung disease, breastfeeding, and ability to return for repeated visits, and those facts may later affect imaging, methotrexate safety, surgery, pain treatment, and follow-up.

Examination starts with repeated vital signs, mental state, perfusion, and abdominal signs. Pelvic examination is explained and consented to. It is used only when it can identify bleeding, infection, tissue, or tenderness that changes care. A reassuring examination is repeated if symptoms change.

Diagnostic strategy#

Confirm pregnancy and assess stability#

The initial evaluation includes quantitative serum hCG, complete blood count because bleeding is present, and blood group testing according to the current local pathway. Kidney and liver tests are obtained if medical treatment for ectopic pregnancy may become relevant or another diagnosis suggests them. Urinalysis and infection testing are driven by symptoms and consent.

Transvaginal ultrasound is the central location test, often paired with transabdominal views to assess the pelvis and free fluid. The 2025 ACR criteria rate both transvaginal and transabdominal pelvic ultrasound as usually appropriate initial imaging for first-trimester bleeding. Computed tomography is not routine for this question, although necessary imaging for another life-threatening diagnosis should not be withheld merely because of pregnancy.

Use precise ultrasound language#

The scan should describe the uterus, endometrium, adnexa, ovaries, and pelvic fluid. Under the 2024 multisociety lexicon, pregnancy of unknown location is a diagnostic placeholder only when positive hCG is accompanied by no definite or probable intrauterine pregnancy and no definite or probable ectopic pregnancy on transvaginal ultrasound.

The label does not mean ectopic pregnancy, miscarriage, or early intrauterine pregnancy has been diagnosed. Each remains possible. Clear terms reduce the risk that a placeholder becomes a final diagnosis in the chart.

Do not ask hCG to locate the pregnancy#

One hCG value cannot establish location: an empty uterus above a locally chosen discriminatory value raises concern but is not proof of ectopic pregnancy and must not trigger automatic methotrexate in a desired pregnancy. Assays, dating, multiple gestation, ultrasound quality, and normal biologic variation limit a universal cutoff.

For a stable pregnancy of unknown location, NICE recommends two serum hCG measurements as close as possible to 48 hours apart, with later testing directed by senior review. It also says symptoms take priority over hCG and that hCG should not be used to determine location. U.S. emergency guidance likewise cautions against excluding ectopic pregnancy with hCG after an indeterminate ultrasound and requires specialty consultation or close follow-up.

Serum progesterone is not added as a shortcut to distinguish intrauterine from ectopic pregnancy in the NICE pathway. Uterine aspiration is not a casual diagnostic test in a desired pregnancy that may still be developing.

Progressive results and interpretation#

Quantitative hCG is 1,120 IU/L. Hemoglobin is within the laboratory reference range, blood group is RhD positive, and kidney and liver tests are normal. Transvaginal ultrasound shows no definite or probable intrauterine pregnancy, no definite or probable ectopic pregnancy, and no concerning free fluid. A small left ovarian structure is interpreted as a likely corpus luteum without torsion features.

This is a pregnancy of unknown location. The hCG value does not make the empty uterus diagnostic. The patient remains stable, pain improves, and she can return to the same early-pregnancy service. A named clinician schedules repeat hCG close to 48 hours and gives a direct 24-hour emergency contact.

The second hCG value is 1,900 IU/L, a rise of about 70 percent. This supports continued trophoblastic development and meets the NICE branch in which a developing intrauterine pregnancy is likely, but ectopic pregnancy still cannot be excluded. Symptoms are again reviewed before the number: spotting is minimal and pain has nearly resolved.

Repeat transvaginal ultrasound eight days after the first shows a gestational sac with a yolk sac implanted in a normal intrauterine location, without an adnexal mass or free fluid. Under the multisociety lexicon, the yolk sac establishes a definite intrauterine pregnancy. The pregnancy's location is now resolved. Developmental assessment and dating continue through obstetric follow-up; the earlier hCG rise did not establish this result by itself.

Management plan#

Manage the unresolved interval as an active plan#

The patient receives oral and written instructions that pregnancy location remains uncertain and that ectopic pregnancy is still possible. The plan names the date, laboratory, and imaging site. It names the responsible clinician, result-notification method, and backup if she cannot attend. Pain relief is selected for pregnancy and individual health constraints; exact drug dosing is intentionally omitted.

Observation is acceptable only while she remains stable and follow-up is reliable. It is not passive waiting. The team checks symptoms at every contact and changes course for worsening pain, bleeding, dizziness, or new examination findings regardless of the last hCG value.

No methotrexate, uterine procedure, or surgery is offered solely because the first scan is empty. Premature treatment could end a desired intrauterine pregnancy. Once the repeat scan establishes a normal intrauterine location, routine prenatal care is arranged while persistent or recurrent pain is reassessed for nonpregnancy and rare heterotopic causes.

If ectopic pregnancy becomes likely or confirmed#

Treatment is chosen with obstetrics and gynecology according to stability, imaging, and hCG pattern. It is chosen according to symptoms, pregnancy location and size, and evidence of rupture. It is chosen according to reproductive goals, contraindications, and follow-up capacity.

• Expectant management: An option only for carefully selected, clinically stable patients with minimal or no pain, an appropriately low and declining hCG pattern, no rupture concern, and reliable serial follow-up. Falling hCG does not remove rupture risk until resolution.
• Methotrexate: Considered for a stable, unruptured ectopic pregnancy when an intrauterine pregnancy has been excluded, follow-up is dependable, and clinical and laboratory constraints are satisfied. Breastfeeding, immune deficiency, significant blood-count abnormality, active liver or kidney disease, clinically important lung disease, active peptic-ulcer disease, inability to complete monitoring, and other medicine interactions can make it unsafe. Exact regimen and dosing require specialist and pharmacist verification.
• Surgery: Required for hemodynamic instability or suspected rupture and considered for high-risk imaging features, contraindication or inadequate response to medical treatment, inability to follow safely, or informed patient preference. Procedure choice considers the other tube, fertility goals, bleeding, anatomy, and surgical expertise.

If early pregnancy loss is confirmed rather than ectopic pregnancy, expectant, medication, and procedural options are discussed according to stability and preference. A claimed completed miscarriage without a previously confirmed intrauterine pregnancy still requires follow-up until ectopic pregnancy is no longer plausible.

Address RhD decisions with current guidance#

RhD testing and immune-globulin recommendations have changed and differ by gestational age, confirmed outcome, procedure, and jurisdiction. The team does not apply an old blanket rule to threatened bleeding, pregnancy of unknown location, confirmed loss, and ectopic treatment as if they were identical. Current ACOG guidance, the June 2026 NICE update, product availability, and local policy are checked and the decision is documented. The patient in this analysis is RhD positive, so prophylaxis is not indicated for her.

Escalation, referral, and safety net#

Immediate emergency evaluation and obstetric or surgical response are required for hemodynamic instability, collapse, fainting, new shoulder-tip pain, sudden or severe abdominal or pelvic pain, guarding or rebound, marked pallor, breathing difficulty, confusion, or bleeding accompanied by weakness or other signs of substantial blood loss. A reassuring prior hCG rise does not lower this threshold.

Prompt early-pregnancy or gynecology review is needed for worsening or persistent pain, increasing bleeding, an hCG trend outside the expected branch, a repeat scan that remains indeterminate, adnexal or free-fluid findings, inability to obtain scheduled testing, or diagnostic disagreement. Emergency clinicians should not discharge an indeterminate scan without either specialty consultation or a closed-loop follow-up arrangement.

The patient receives a 24-hour contact route staffed by people familiar with early-pregnancy complications. If that service is unavailable or unreachable during worsening symptoms, she is instructed to use emergency services rather than wait for the next scheduled blood draw.

Communication, shared decisions, and equity#

A clear explanation is: "The test confirms pregnancy, but today's scan does not yet show where it is implanted. That can happen because the pregnancy is early, because it has stopped developing, or because it is outside the usual location. Your current examination is reassuring, but only follow-up can separate those possibilities safely."

The clinician avoids saying the hCG "doubled normally" or that the uterus is "empty" without context. The terms early pregnancy loss and cardiac activity follow the multisociety lexicon and avoid language that implies blame. Pregnancy intention is asked directly. The patient is not pressured toward treatment or surveillance through fear.

Serial care can be burdensome. Transportation, rural distance, and child care affect whether follow-up is safe. So do hourly work, insurance, and laboratory hours. So do language, disability access, and portal privacy. The team consolidates visits, uses professional interpreters, provides written results in accessible language, and chooses hospital observation when outpatient return cannot be made reliable.

Transgender and nonbinary people can become pregnant and may avoid care after prior discrimination. Names, pronouns, anatomy, and pregnancy goals are discussed respectfully without assuming identity. Screening for coercion or partner violence occurs privately. Local legal complexity is handled with current institutional guidance and specialist support without delaying stabilizing emergency care.

Follow-up and contingencies#

Pregnancy of unknown location is followed until a definite location or documented resolution is reached. A hormone trend alone is not the endpoint. The responsible service records every value, symptoms at the time of the value, the next required action, and confirmation that the patient received the plan.

After the definite intrauterine pregnancy is found, obstetric follow-up confirms developmental progression. It addresses ongoing bleeding, pain, and prenatal care. It addresses medications and patient questions. New severe unilateral pain still requires assessment because ovarian disease, appendicitis, and rare heterotopic pregnancy are not erased by an intrauterine finding.

If hCG falls instead, the team continues the selected pathway until resolution or a definitive diagnosis. Plateauing, slow decline, or persistent positive testing prompts senior review for ectopic pregnancy or retained pregnancy tissue. If the patient misses testing, the team attempts direct contact through agreed safe methods and follows institutional outreach policy; silence is not treated as a reassuring result.

Reasoning traps and alternative pathways#

• Calling pregnancy of unknown location a diagnosis: It is a temporary state requiring follow-up, not a synonym for ectopic pregnancy.
• Using the last menstrual period as exact dating: Irregular ovulation can make the pregnancy earlier than expected.
• Treating one hCG value as a map: A serum value cannot identify implantation location.
• Using a discriminatory boundary as a treatment trigger: Nonvisualization increases concern but does not prove ectopic pregnancy or justify automatic methotrexate.
• Letting a reassuring rise cancel symptoms: Ectopic pregnancy can have a rising hCG pattern. New pain or instability overrides the prior trend.
• Declaring completed loss after an empty scan: Without a previously confirmed intrauterine pregnancy, a resolving ectopic pregnancy remains possible.
• Reassuring from absent risk factors: Many ectopic pregnancies occur without a known risk factor.
• Treating follow-up as administration: Reliable transport, result ownership, emergency access, and direct communication are clinical safety requirements.
• Forgetting nonobstetric disease: Urinary, gastrointestinal, ovarian, and surgical causes can coexist with pregnancy.

An alternative branch would move directly to resuscitation and surgery if shock or rupture appeared. A definite adnexal pregnancy in a stable patient would prompt expectant, medical, or surgical counseling based on strict eligibility. A falling hCG with no confirmed location would remain under surveillance. Fertility treatment would raise concern for heterotopic pregnancy even after an intrauterine pregnancy is seen.

Evidence limits and what could change#

hCG trajectories overlap among developing intrauterine pregnancies, ectopic pregnancies, and losses, published minimum-rise and decline boundaries differ by starting value, assay, population, and guideline, and ultrasound interpretation depends on equipment, operator, gestational timing, anatomy, and terminology. A numerical rule cannot replace symptom reassessment.

NICE NG126 was updated in June 2026 and provides a defined United Kingdom pathway. ACEP addresses emergency evaluation in the United States. ACR ranks imaging choices, while the 2024 multisociety lexicon standardizes language. ACOG guidance informs ectopic and loss care, including evolving RhD recommendations. Local practice, law, specialist access, and patient preferences still shape implementation.

The reassuring outcome in this case analysis depends on stable symptoms, a reliable return system, an appropriately rising hCG value, and repeat imaging that establishes location. Worsening pain, free fluid, or falling hemoglobin would change management immediately. So would an adnexal finding, a nonreassuring trend, or inability to return.

Key points#

• In early-pregnancy pain and bleeding, stabilize first and keep ectopic pregnancy in view even when risk factors are absent.
• Pregnancy of unknown location is a temporary classification that requires follow-up to a definite location or resolution.
• hCG describes trophoblastic change but cannot locate a pregnancy; symptoms and ultrasound remain decisive.
• Do not start methotrexate or an irreversible procedure from an empty scan and a chosen hCG boundary alone.
• Safe serial care requires explicit emergency thresholds, a 24-hour route, named result ownership, and a realistic return plan.